Page 80 - ITPS-8-2

INNOSC Theranostics and
Pharmacological Sciences Ketamine and SOD activity in schizophrenia

administration significantly (P < 0.05) reduced elevated Author contributions
SOD activity in KET-treated mice. This reduction was
accompanied by behavioral symptom amelioration, Conceptualization: All authors
consistent with clinical findings in schizophrenic patients Formal analysis: Yusuf Usman, Adegbuyi Oladele
Aderibigbe
receiving RISP. The ability of antipsychotic medications Investigation: Yusuf Usman
40
to modulate the oxidative stress defense system may Methodology: All authors
contribute to their therapeutic efficacy.
Writing-original draft: Yusuf Usman
5. Conclusion Writing-review & editing: Adegbuyi Oladele Aderibigbe,
Fatai Adewale Fehintola
This study confirms that KET-induced NMDA receptor
blockade leads to hyperactivity, cognitive impairment, Ethics approval and consent to participate
and elevated SOD enzymatic activity, mirroring key All experimental procedures were approved by the Animal
schizophrenia-like phenotypes. Elevated SOD enzymatic Care and Use Research Committee (ACURC), Faculty
activity was observed as a response to repeated sub- of Basic Medical Sciences, Federal University of Health
anesthetic doses of KET administration. The heightened Sciences Ila-Orangun (FUHSI/BMS/AREC/2401). All the
SOD enzymatic activity likely represents a compensatory procedures were in-line with the guidelines set forth by the
mechanism aimed at mitigating the effects of oxidative NIH for the care and use of laboratory animals.
stress induced by KET administration. However, this
response may also contribute to the persistence or Consent for publication
exacerbation of neurobiological and behavioral symptoms Not applicable.
associated with schizophrenia.
The findings suggest that oxidative stress plays a central Availability of data
role in the pathophysiology of KET-induced schizophrenia Data supporting the findings of this study are available
models. Elevated SOD enzymatic activity highlights from the corresponding author upon reasonable request.
the dysregulation of antioxidant defenses in response
to excessive ROS production. Targeting this oxidative Further disclosure
imbalance with antioxidant therapies holds potential for The paper has been uploaded to or deposited in a preprint
alleviating neurobiological and behavioral symptoms. (bioRxiv repository, with MS ID#: BIORXIV/2024/610179.
Further investigations could focus on assessing oxidative doi: https://doi.org/10.1101/2024.08.28.610179 https://
and antioxidant markers, inflammatory cytokines, and biorxiv.org/cgi/content/short/2024.08.28.610179v1).
neurotransmitter parameters to explore their modulation
by therapeutic interventions. References
These results emphasize the interplay between SOD 1. Ng F, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric
enzymatic activity and NMDA receptor dysfunction disorders: Evidence base and therapeutic implications. Int J
in schizophrenia and underscore the importance of Neuropsychopharmacol. 2008;11(6):851-876.
antioxidant approaches that restore redox balance. Such doi: 10.1017/S1461145707008401
approaches may also improve behavioral and cognitive 2. Murray AJ, Rogers JC, Katshu MZUH, Liddle PF,
outcomes in schizophrenia models. Upthegrove R. Oxidative stress and the pathophysiology and
symptom profile of schizophrenia spectrum disorders. Front
Acknowledgments Psychiatry. 2012;12:703452.
I would like to acknowledge the efforts of all the technical doi: 10.3389/fpsyt.2021.703452
staff of the Department of Pharmacology and Therapeutics 3. Dudzińska E, Szymona K, Bogucki J, et al. Increased
Laboratory, University of Ibadan for their technical markers of oxidative stress and positive correlation low-
assistants. grade inflammation with positive symptoms in the first
episode of schizophrenia in drug-naïve patients. J Clin Med.
Funding 2022;11(9):2551.
None. doi: 10.3390/jcm11092551

Conflict of interest 4. Padurariu M, Ciobica A, Dobrin I, Stefanescu C. Evaluation
of antioxidant enzymes activities and lipid peroxidation
The authors declare that they have no competing interests. in schizophrenic patients treated with typical and atypical

Volume 8 Issue 2 (2025) 74 doi: 10.36922/itps.6372